Introduction
============

Acute coronary syndrome (ACS) is a type of cardiovascular disease (CVD) that occurs as a result of an acute obstruction in the coronary arteries, and it represents a leading cause of mortality and disability worldwide ([@b1-ijmm-41-01-0220]--[@b3-ijmm-41-01-0220]). A previous epidemiological survey revealed that \~50% of cardiovascular mortalities are due to ACS ([@b4-ijmm-41-01-0220]). Therefore, it is necessary to clarify the underlying biological mechanisms of ACS to enable early diagnosis and treatment of the disease.

The traditional diagnosis of ACS is achieved by a combination of electrocardiogram (ECG) results and the detection of specific serum markers ([@b5-ijmm-41-01-0220]). However, the sensitivity of ECGs is generally \<50% and the application of serum markers, including creatine kinase isoenzyme MB (CK-MB), cardiac troponin (cTn)I and cTnT, also has limitations ([@b6-ijmm-41-01-0220]). Despite the high specificity of cTnT and cTnI, they may only be detected 6--12 h following myocardial ischemia, which is insufficient for early diagnosis and treatment of ACS prior to myocardial injury ([@b7-ijmm-41-01-0220]). The development of novel, sensitive and accurate ACS biomarkers are urgently required to enable the early diagnosis and treatment of ACS.

Epigenetics are defined as stable, heritable alterations in gene expression, which are not due to changes in the DNA sequence ([@b8-ijmm-41-01-0220]). The role of epigenetics has mainly been evaluated in relation to cancer ([@b9-ijmm-41-01-0220]), but selected previous studies have explored epigenetic involvement in CVD development and progression ([@b10-ijmm-41-01-0220]--[@b13-ijmm-41-01-0220]). DNA methylation-induced genetic repression is a major type of epigenetic modification ([@b14-ijmm-41-01-0220]). DNA methylation occurs at the C5 position of cytosine by the covalent modification of a methyl group, which is most commonly found in 5′-C-phosphate-G-3′ (CpG) dinucleotides ([@b15-ijmm-41-01-0220]). Alterations in genome-wide and site-specific DNA methylation have been described in CVD, although their specific functions are still largely uninvestigated ([@b16-ijmm-41-01-0220],[@b17-ijmm-41-01-0220]). Altered DNA methylation (hyper methylation or hypomethylation) is one of the early events in the pathogenesis of ACS ([@b18-ijmm-41-01-0220],[@b19-ijmm-41-01-0220]). Hypermethylation of specific promoter regions of crucial genes, such as transcription factor genes, can repress the expression of these genes and alter biological functions, which in turn increases the risk of ACS ([@b20-ijmm-41-01-0220]). Furthermore, it has been reported that numerous risk factors, including hypertension ([@b21-ijmm-41-01-0220],[@b22-ijmm-41-01-0220]), diabetes ([@b23-ijmm-41-01-0220]--[@b26-ijmm-41-01-0220]), atherosclerosis ([@b27-ijmm-41-01-0220]--[@b30-ijmm-41-01-0220]) and smoking ([@b31-ijmm-41-01-0220],[@b32-ijmm-41-01-0220]), associated with the development of ACS may cause epigenetic alterations. These previous studies suggested that the detection of DNA methylation alterations may be a promising tool for early ACS prediction and diagnosis. However, systematic analyses of the changes to genome-wide DNA methylation in patients with ACS are still lacking. In the present study, the genome-wide aberrant DNA methylation patterns predominantly associated with ACS were explored. Additionally, the differentially methylated (DM) regions associated with ACS pathogenesis were characterized, and novel DNA methylation biomarkers potentially beneficial to the early diagnosis of ACS were identified.

Materials and methods
=====================

Study subjects
--------------

The present study recruited 81 patients with ACS, 74 patients with stable coronary artery disease (SCAD) and 53 control subjects. The patients with CAD in the present study were admitted to the Department of Cardiology of Jinling Hospital (Nanjing, China) between January, 2014 and December, 2016, who were undergoing clinically necessary coronary angiography. Angiograms of all patients with CAD revealed ≥50% stenosis in a minimum of one coronary artery. The 81 patients with ACS included patients with acute myocardial infarction and unstable angina, with Braunwald classification II or III who exhibited a positive cardiac biomarker result (cTnI ≥0.090 ng/ml or cTnT ≥0.014 ng/ml), acute ischemic-type chest pain (lasting for \>15 min, duration from symptom onset to emergency admission within 72 h) and characteristic ECGs. The 74 patients with SCAD had a normal ECG and documented normal left ventricular contractility, with the exception of possible minor nonspecific ST-T features, and they had a ≥1 year history without any cardiac events or procedures suggestive of ACS. The exclusion criteria for the patients with CAD included mild disease identified on angiography (a stenosis of 10--50% of the luminal diameter in all three coronary arteries), prior coronary revascularization and the presence of renal disease. The 53 control subjects were recruited to the study from routine health examinations at Jinling Hospital over the same period. The control patients had a normal physical examination, ECG and laboratory tests, and were did not show signs of other diseases, including hyperlipidemia, hypertension and diabetes mellitus, or any clinically evident signs of atherosclerosis. The clinicopathological features of all the patients and controls are listed in [Table I](#tI-ijmm-41-01-0220){ref-type="table"}. The present study was approved by the Ethics Committee of Jinling Hospital and all the recruited subjects provided written informed consent prior to the study.

Blood sampling
--------------

Blood samples were collected from the patients with 81 ACS and 74 patients with SCAD in tubes containing EDTA immediately following their hospitalization. The 53 control samples were drawn from the elbow vein of a paired healthy individual on an empty stomach. The samples were stored at −80°C prior to analysis.

DNA isolation and sodium bisulfite modification
-----------------------------------------------

Genomic DNA was isolated from 100 µl blood using the DNeasy Blood and Tissue kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer\'s protocol. The quality and quantity of the extracted genomic DNA was analyzed with a NanoDrop™ 2000 Spectrophotometer. Bisulfite modification of 1 *μ*g DNA was conducted using an EpiTect Bisulfite kit (Qiagen, Inc.) according to the manufacturer\'s protocol.

Infinium HumanMethylation450 assay
----------------------------------

A total of 3 patients with ACS were randomly selected and paired with 3 control subjects for the Infinium HumanMethylation450 assay (Illumina, Inc., San Diego, CA, USA). The Infinium HumanMethylation450 assay was performed according to the manufacturer\'s standard protocol. Processed methylation chips were scanned using an iScan reader (Illumina, Inc.). Paired control samples were processed on the same chip and all samples were processed at the same time to avoid chip-to-chip variation. The assays were conducted in the Beijing Genomics Institute (Beijing, China).

Methylation-specific semi-quantitative polymerase chain reaction (MSP) analysis
-------------------------------------------------------------------------------

In the present study, MSP was developed for the detection of mothers against decapentaplegic homolog 3 (SMAD3; Chr1:67356838-Chr1:67356942) methylation in 81 patients with ACS, 74 patients with SCAD and 53 healthy individuals using two pairs of primers, one was specific for the methylated alleles while the other was specific for the unmethylated alleles. Primer sequences are listed in [Table II](#tII-ijmm-41-01-0220){ref-type="table"}. The thermocycling conditions were as follows: Complete denaturation of the DNA at 95°C for 5 min; 35 cycles of denaturation at 95°C for 30 sec, annealing at 58°C for 30 sec, extension at 72°C for 45 sec; and a final extension at 72°C for 10 min. The MSP products were assessed by electrophoresis in 2% agarose gels with 0.5 *μ*g/ml ethidium bromide and analyzed using a UVC1-1100 SmartView Pro 1100 Imaging system with version 1.0.0.2 software (Major Science, Saratoga, CA, USA). Images demonstrating the different methylation patterns were captured.

Sequenom MassARRAY
------------------

Primer pairs were designed using EpiDesigner ([epidesigner.com](http://epidesigner.com)) and are presented in [Table II](#tII-ijmm-41-01-0220){ref-type="table"}. MassArray analysis was performed in triplicate using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY Analyzer 4; Sequenom, San Diego, CA, USA) according to manufacturer\'s protocol in 8 ACS patients, 8 SCAD patients and 8 healthy individuals randomly from each group. The experiments were conducted at the Beijing Genomics Institute.

Differential methylation analysis
---------------------------------

The Infinium HumanMethylation450 assay data were normalized using internal controls (normalization control probe pairs, which were designed to target the same region within housekeeping genes and had no underlying CpG sites in the probe) with GenomeStudio software (version 2011.1; Illumina, Inc.). For quality control, methylation measures of P\>0.05 and samples with a CpG coverage \<95% were removed. The methylation levels of CpG sites were calculated as the β score \[β score = intensity of the methylated allele/(intensity of the unmethylated allele + intensity of the methylated allele + 100)\]. Limma software (version 3.24.15; bioconductor. org/packages/release/bioc/html/limma.html) was used to perform paired t-tests followed by Benjamini and Hochberg correction for multiple testing in order to identify DM CpG sites in the ACS group vs. the control group. Sites with a Benjamini and Hochberg-corrected value of P\<0.05 and a β score ≥0.1 were considered to be significantly statistically different. A volcano plot was used to display the mean DNA methylation differences for the DM CpG sites. Hierarchical clustering of the methylation data was performed when the β score was ≥0.2.

Functional annotation of DM CpG sites
-------------------------------------

The enrichment analysis of the methylated regions for Gene Ontology (GO) ([@b33-ijmm-41-01-0220]) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@b34-ijmm-41-01-0220]) pathways was conducted using the Genomic Regions Enrichment of Annotations Tool ([@b35-ijmm-41-01-0220]). Binomial statistics with false discovery rate (FDR) correction were used to identify significantly enriched ontologies. The most significant and replicable corresponding genes were selected to be candidate markers for ASC detection. These genes were chosen from the results of the differential methylation tests at the site, gene region and gene island region levels, and had a β score difference between the ACS and control samples of \>0.3.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS software (version 20.0; SPSS, Inc., Chicago, IL, USA). Normally distributed values are expressed as the mean ± standard deviation. A one-sample Kolmogorov-Smirnov test was used to evaluate the normality of distribution of the variables. The significance of differences between variants among groups was analyzed by one-way analysis of variance, and the differences between groups were subsequently determined using a post hoc Fisher\'s least significant difference test. The differences in cTnI and CK-MB between two groups were analyzed using the Student\'s t-test. The Kruskal-Wallis H test was performed for non-parametric data. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Normalization of methylation data
---------------------------------

For the methylated sites identified by Illumina HumanMethylation450 assay, the original data of the 3 patients with ACS and 3 paired controls were normalized to the internal controls to eliminate the possibility of system error, and the β scores were subsequently calculated. The β scores were generated based on the intensity of the methylated and unmethylated probes, and were used as an indicator of the degree of methylation at each CpG site. Subsequently, a built-in detection score filter was used prior to further calculations. This only left values with significantly higher mean signal intensities from multiple probes for a given CpG locus compared with those of the negative control in the same set of chip data. The average number of loci detected for the three pairs of ACS and control samples was 484,352 covering 42,343 genes ([Table III](#tIII-ijmm-41-01-0220){ref-type="table"}). The density plots of the β score for the 6 samples exhibited a bimodal distribution ([Fig. 1](#f1-ijmm-41-01-0220){ref-type="fig"}). These results indicate that the hybridization and amplification conditions were uniform for all samples.

Epigenome-wide DNA methylation analysis
---------------------------------------

Using Benjamini and Hochberg correction for multiple comparisons, a total of 11,342 (2.34%) DM CpG sites covering 5,073 genes were identified in patients with ACS compared with the control patients ([Table III](#tIII-ijmm-41-01-0220){ref-type="table"}). Among the 11,342 DM CpG sites, 8,865 (78.2%) covering 5,071 genes were significantly hypomethylated, while 2,477 (21.8%) covering 1,746 genes were significantly hypermethylated in the ACS samples ([Table III](#tIII-ijmm-41-01-0220){ref-type="table"}). A volcano plot of the data exhibited the mean DNA methylation differences for all CpG sites ([Fig. 2](#f2-ijmm-41-01-0220){ref-type="fig"}). The frequencies of all significant CpG sites between the ACS and control groups were analyzed ([Table IV](#tIV-ijmm-41-01-0220){ref-type="table"}). A total of 9.04% (224) of the hypermethylated CpG sites and 11.8% (982) of the hypomethylated CpG sites had an absolute ACS/control group methylation difference ≥20%. [Fig. 3](#f3-ijmm-41-01-0220){ref-type="fig"} presents a hierarchical cluster analysis of the 1,206 CpG sites that distinguished the ACS samples from the control samples.

Genomic distribution of DM CpG sites
------------------------------------

Significant DM CpG sites were analyzed based on their region and island region level throughout the genome ([Table V](#tV-ijmm-41-01-0220){ref-type="table"}). There were 6 gene-based regions, including the transcription start site (TSS)1500, TSS200 (within 200 base pairs of a TSS), 5′-untranslated region (5′-UTR), 1stExon, body and 3′-UTR. In addition, there were 5 CpG island-based regions, including the island, N-Shore, S-Shore, N-Shelf and S-Shelf sites. The gene and island regions were used to calculate the methylation index. All the given region definitions were based on the original Illumina methylation annotation for the Human Methylation450 BeadChip array. The gene-based variant of the region-level test resulted in the identification of 4,809 significant DM CpG sites, which covered 2,188 genes. This number contained all unique genes, which resulted from six different, separately analyzed gene categories: TSS1500 (349 genes), TSS200 (182 genes), 5′-UTR (246 genes), 1stExon (31 genes), body (1,250 genes) and 3′-UTR (130 genes). Similarly, the CpG island-based variant of the region-level test resulted in 1,224 DM CpG sites located in islands, and 1,593 and 1,247 DM CpG sites distributed inside the N-Shore and S-Shore, respectively, while 751 and 685 DM CpG sites were located in the N-Shelf and S-Shelf, respectively. In total, 5,500 unique DM CpG sites covering 2,322 genes were identified among the five CpG-related regions.

The genomic regions of the significantly hypermethylated or hypomethylated CpG sites were distributed similarly ([Table VI](#tVI-ijmm-41-01-0220){ref-type="table"}). The largest portion of hypermethylated CpGs (60.36%) were located in the body of the genes and subsequently decreased in other categories (15.17% in TSS1500, 6.88% in TSS200, 10.01% in the 5′-UTR, 1.72% in the 1stExon and 5.86% in the 3′-UTR). In addition, over half (54.06%) of the significantly hypomethylated CpG sites were located in the body, while the rest were distributed in the TSS1500 (18.16%), TSS200 (9.24%), 5′-UTR (10.89%), 1stExon (1.47%) and 3′-UTR (5.73%) regions. Furthermore, the distribution analysis of DM CpG sites in island regions revealed that 18.5% (190) of the significantly hypermethylated CpG sites were in CpG island regions, with 47.81% (491) in CpG shores and 33.69% (346) in shelf regions. As for the significantly hypomethylated CpG sites, 23.12% (1,034) were located in islands, while the majority were identified in shore (52.52%) or shelf (24.36%) regions ([Table VII](#tVII-ijmm-41-01-0220){ref-type="table"}), suggesting they serve a potential role in genomic instability.

GO term and KEGG pathway enrichment analyses of the DM CpG sites
----------------------------------------------------------------

To identify the functions and pathways possibly influenced by the genes nearest the DM CpG sites in patients with ACS compared with the controls, GO term and KEGG pathway enrichment analyses were performed ([Fig. 4](#f4-ijmm-41-01-0220){ref-type="fig"}). There were 767 functional categories of DM genes (FDR \<0.05), the largest portion of the functional terms comprised of biological processes (603), while the rest were cellular components (76) or molecular functions (88). When the biological processes were used for categorization, it was observed that the most enriched groups included immune system processes, the regulation of responses to stimuli and cell activation. Categorization by cellular components indicated that proteins encoded by the analyzed genes were mainly associated with the cytoplasm. The molecular function category demonstrated significant enrichment for phospholipid, protein and lipid binding activities. [Fig. 4](#f4-ijmm-41-01-0220){ref-type="fig"} presents the top 10 terms of the three GO categories ranked by statistical significance.

KEGG pathway analysis revealed a significant enrichment of genes associated with the hematopoietic cell lineage and endocytosis ([Table VIII](#tVIII-ijmm-41-01-0220){ref-type="table"} and [Fig. 5](#f5-ijmm-41-01-0220){ref-type="fig"}). Among them, the immune system, and the transport and catabolism pathways attracted were ranked highest in terms of significance.

Selection of significant genes as possible diagnostic markers
-------------------------------------------------------------

The selection criteria used to select potential diagnostic marker genes included CpG sites that were methylated in the site, gene and gene island region, and a β score difference between the ACS and control samples of \>0.3. Following filtering, a list of 19 hypermethylated and 17 hypomethylated CpG sites were selected that matched these criteria ([Table IX](#tIX-ijmm-41-01-0220){ref-type="table"}). These methylated CpG sites were mapped to 37 known genes.

CpG methylation validation
--------------------------

The methylation state of the representative TSS1500 region (SMAD3; Chr1:67356838-Chr1:67356942) on the basis of DM magnitude was detected by MSP ([Figs. 6](#f6-ijmm-41-01-0220){ref-type="fig"} and [7A](#f7-ijmm-41-01-0220){ref-type="fig"}) and Sequenom MassARRAY ([Fig. 7B](#f7-ijmm-41-01-0220){ref-type="fig"}). These results were compared with the results from the HumanMethylation450 array. The frequency of semi-methylated sites (ummethylated/methylated status) in patients with ACS was notably higher than that in the patients with SCAD and the healthy donors ([Fig. 7A](#f7-ijmm-41-01-0220){ref-type="fig"}). The mean methylation level was identified as being significantly lower in patients with ACS compared with the SCAD and healthy control groups ([Fig. 7B](#f7-ijmm-41-01-0220){ref-type="fig"}).

Discussion
==========

To the best of our knowledge, the present study presents the first genome-wide DNA methylation profiling of 3 paired ACS and normal human blood samples, using a high-throughput DNA methylation microarray covering \>450,000 CpG sites on the human genome. The DM CpGs identified were enriched in genes associated with immune system processes, the regulation of responses to stimuli and cell activation, which suggests that they are of potential mechanistic and therapeutic relevance.

The impact of epigenetic mechanisms in cardiovascular pathophysiology is emerging as a key participant in the interface between genotype and phenotype variability. Several previous studies have focused on the role of DNA methylation in the development of atherosclerosis and CVD. Hiltunen *et al* ([@b27-ijmm-41-01-0220]) reported that a global hypomethylation of DNA was present in advanced human, mouse and rabbit atherosclerotic lesions. Notably, the results of Kim *et al* ([@b36-ijmm-41-01-0220]) indicated that elevated peripheral blood leukocyte DNA methylation was positively associated with the prevalence of CVD predisposing conditions and obesity in Chinese Singaporeans. A recent study also revealed that lower global DNA methylation is associated with higher cardiovascular risk in postmenopausal women ([@b37-ijmm-41-01-0220]). These studies led to the use of DNA methylation as a novel biomarker for CAD. However, the majority of their results were obtained from animal experiments or gene-specific DNA methylation, which lack of the systematic analysis of genome-wide changes to DNA methylation in patients with ACS. Zaina *et al* ([@b38-ijmm-41-01-0220]) identified an atherosclerosis-specific DNA methylation profile that highlighted the contribution of different genes and pathways to the disorder; however, this study did not take into account the characteristics of acute onset in patients with atherosclerotic CVD.

The present study analyzed the changes to genome-wide DNA methylation in patients with ACS using the Illumina HumanMethylation450 assay. A total of 11,342 CpG sites across the whole genome demonstrated statistically significant DM in the ACS samples compared with the control samples. The majority of the DM CpG sites were hypomethylated (8,865; 78.2%) rather than hypermethylated (2,477; 21.8%), which was consistent with the results of a previous methylation study in atherosclerotic lesions and CAD ([@b28-ijmm-41-01-0220]). In addition, global hypomethylation, particularly in repeated sequences, serves an important role in increasing chromosomal instability and may lead to ACS ([@b39-ijmm-41-01-0220]). This suggests that alteration of the DNA methylation profile, particularly hypomethylation, is an important process in the pathogenesis of ACS. Sharma *et al* ([@b40-ijmm-41-01-0220]) proposed that genomic DNA methylation in patients with CAD is significantly altered, as higher genomic DNA methylation changes were observed in patients with CAD than in controls. Kim *et al* ([@b36-ijmm-41-01-0220]) examined the association between peripheral blood leukocyte global genomic DNA methylation and the prevalence of CVD (myocardial infarction and stroke) or its risk factors (hypertension and diabetes) to verify the value of DNA methylation as a CVD risk biomarker. However, Kim *et al* ([@b36-ijmm-41-01-0220]) only compared differences in the overall methylation status between normal subjects and patients with coronary heart disease; further details on the differences in DNA methylation sites were not mentioned.

The genomic distribution of significant CpG sites revealed that significantly DM CpG sites were more frequently located at the body (55.3%) and shore (51.6%) sites. It has been previously reported that methylation at the CpG island shore regions regulates promoter activity ([@b41-ijmm-41-01-0220]), and that differential DNA methylation in gene bodies and intergenic loci indicates more complex mechanistic implications, as they are considered to promote transcriptional elongation, and to regulate gene splicing and enhancer activities ([@b42-ijmm-41-01-0220]).

The GO term and KEGG pathway enrichment analyses results demonstrated a significant enrichment of the corresponding methylated genes associated with the immune system processes, regulation of responses to stimuli and cell activation, which are all associated with the hematopoietic cell lineage and endocytosis signaling pathways. The proteins encoded by the corresponding methylated genes were mainly associated with the cytoplasm, and were enriched in the molecular functions of phospholipid, protein and lipid binding activities. These results are highly consistent with data from a recent genome-wide systematic pathway analysis of body mass index, which provided insights into the genetics of CVD and its risk factors ([@b43-ijmm-41-01-0220]). The results of the present study revealed a significant enrichment to immune system processes in the ACS samples, which may be due to the altered maturation status and possible immune exhaustion of immune cells in the peripheral blood of patients with ACS ([@b44-ijmm-41-01-0220]). Additionally, the neutrophil/lymphocyte ratio (NLR) has been identified to be independently associated with the severity and 3-year outcomes of CAD: Patients with higher NLR values had more advanced obstructive CAD and a poorer prognosis ([@b45-ijmm-41-01-0220]). CVD is often accompanied by disorders of lipid metabolism, and previous studies have demonstrated that elevated concentrations of oxidized lipoprotein were associated with the presence and severity of ACS ([@b46-ijmm-41-01-0220],[@b47-ijmm-41-01-0220]). In the present study, the network analysis for GO term and KEGG pathway enrichment of the DM CpG sites revealed significant enrichment change in patients with ACS, which indicated that the methylation alterations at these sites were biologically meaningful.

In the present study, 19 hypermethylated genes (DEAF1, GSTT1, ADAMTS2, SIN3B, HLA-DRB5, ZNF787, LIF, JAKMIP3, WHSC2, HCN2, FAM101A, LRRK1, COL5A3, PKHD1L1, PYROXD1, SERPINB9, LOC391322 and TOM1L1) and 17 hypomethylated genes (TP53INP2, ICA1L, SPSB4, CCS, GSTT1, PCGF3, PDXK, TRPS1, ALPPL2, DEXI, PLAC9, GABRB1, SMAD3, C14orf119, HLA-L, PRKCH and OR2L13) demonstrated a potential association with ACS. These genes may thus represent potential novel candidate biomarkers for the early diagnosis of ACS. Three DM genes were identified that have been deeply studied in CVD: SMAD3, SERPINB9 and PRKCH. SMAD3, a key contributor to the transforming growth factor-β pathway signaling, has been reported to serve an essential role in CAD ([@b48-ijmm-41-01-0220]--[@b51-ijmm-41-01-0220]). Meta-analyses of genome-wide association studies have identified that an intronic single nucleotide polymorphism (SNP) in SMAD3 is associated with protection from CAD ([@b52-ijmm-41-01-0220]). SERPINB9 is most commonly known for its role in the control of granzyme B, which can be applicable for prevention of ACS and atherosclerotic plaque formation in patients with left ventricular remodeling following acute myocardial infarction ([@b53-ijmm-41-01-0220]). However, SERPINB9 also serves a role in suppressing interleukin-1β maturation through inhibiting caspase-1 ([@b54-ijmm-41-01-0220]). Genome-wide association and molecular mechanism studies have revealed that the SNPs rs2230500 ([@b55-ijmm-41-01-0220]) and rs2230500 ([@b56-ijmm-41-01-0220],[@b57-ijmm-41-01-0220]) in PKRCH were significantly associated with the risk of ischemic stroke. However, whether SMAD3, SERPINB9 or PRKCH methylation is associated with the pathogenesis of ACS is currently unknown. The validation experiments performed for SMAD3 and TSS1500 (Chr1:67356838-Chr1:67356942) in the present study indicated that the methylation degree was negatively associated with the pathogenesis of ACS, and this was significantly corrected by the reference results of the Illumina HumanMethylation450 assay.

In conclusion, the present study characterized the genome-wide DNA methylation patterns occurring in ACS, and identified significantly differentiated CpG sites and genes that were correlated with ACS. Additionally, GO term and KEGG pathway enrichment analyses provided information on the processes and pathways that the methylated CpG sites and the participating genes affected. These results may help clarify the role of aberrant methylation in ACS pathogenesis, and provide the basis for future research into potentially abnormally methylated genes as biomarkers for the prevention and early diagnosis of ACS.
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![Density plots of the distribution of the β scores. The β score distribution for the three pairs of samples following normalization, as visualized in density plots.](IJMM-41-01-0220-g00){#f1-ijmm-41-01-0220}

![Volcano plot of the significant differential DNA methylation analysis. All 11,342 sites among the 3 paired acute coronary syndrome and control samples were presented in the volcano plot. Red markers indicate the 11,342 differentially methylated CpG sites between the ACS and the control samples. CpG, 5′-C-phosphate-G-3′; ACS, acute coronary syndrome.](IJMM-41-01-0220-g01){#f2-ijmm-41-01-0220}

![Hierarchical cluster analysis of the significantly DM CpG sites. A hierarchical cluster analysis was performed on the 1,206 significantly differentially methylated CpG sites. DM, differentially methylated; ACS, acute coronary syndrome; CpG, 5′-C-phosphate-G-3′.](IJMM-41-01-0220-g02){#f3-ijmm-41-01-0220}

![Top 10 terms in each GO category ranked according to their statistical significance. The top terms within the biological process, cellular component and molecular function categories are presented. GO, Gene Ontology.](IJMM-41-01-0220-g03){#f4-ijmm-41-01-0220}

![Top 20 Kyoto Encyclopedia of Genes and Genomes pathways ranked according to their statistical significance.](IJMM-41-01-0220-g04){#f5-ijmm-41-01-0220}

![Electrophoresis of the TSS1500 region of mothers against decapentaplegic homolog 3 (Chr1:67356838-Chr1:67356942) following methylation-specific polymerase chain reaction analysis. The M primers and U primers amplified the 141 bp products. M, methylated; U, unmethylated.](IJMM-41-01-0220-g05){#f6-ijmm-41-01-0220}

![Representative measurements of the SMAD3 TSS1500 methylation status. (A) The TSS1500 methylation frequency of SMAD3 in 81 patients with ACS, 74 patients with SCAD and 53 healthy individuals was measured using methylation-specific semi-quantitative polymerase chain reaction analysis. (B) The DNA methylation level of SMAD3 TSS1500 using Sequenom MassARRAY in 8 paired ACS, SCAD and healthy individuals was measured. SMAD3, mothers against decapentaplegic homolog 3; MM, fully methylated; MU, methylated/unmethylated or semi-methylated; ACS, acute coronary syndrome; SCAD, stable coronary artery disease.](IJMM-41-01-0220-g06){#f7-ijmm-41-01-0220}

###### 

Clinical and biochemical characteristics of the participants included in the present study.

  Variable                         Group                                                                   
  -------------------------------- ------------ ---------------------------------------------------------- ------------------------------------------------------------
  Age, years (mean ± range)        64.68±8.18   68.99±13.62                                                72.72±12.93
  Sex, n=m/f                       34/19        47/27                                                      42/39
  History of hypertension, n (%)   0 (0)        58 (78)                                                    61 (75)
  History of diabetes, n (%)       0 (0)        15 (20)                                                    37 (46)
  TC, mmol/l                       4.43±0.47    4.16±0.95                                                  4.50±0.73
  TG, mmol/l                       1.01±0.33    1.48±0.97[a](#tfn1-ijmm-41-01-0220){ref-type="table-fn"}   1.66±0.57[b](#tfn2-ijmm-41-01-0220){ref-type="table-fn"}
  HDL-C, mmol/l                    1.39±0.26    1.07±0.30[b](#tfn2-ijmm-41-01-0220){ref-type="table-fn"}   0.94±0.16[b](#tfn2-ijmm-41-01-0220){ref-type="table-fn"}
  LDL-C, mmol/l                    2.70±0.58    2.74±0.52                                                  2.80±0.33
  Cardiac troponin I, ng/ml        --           0.03±0.01                                                  6.61±17.31[c](#tfn3-ijmm-41-01-0220){ref-type="table-fn"}
  Cardiac troponin T, ng/ml        --           0.015±0.03                                                 0.758±1.95[d](#tfn4-ijmm-41-01-0220){ref-type="table-fn"}
  Creatine kinase-MB, U/l          --           10.24±7.44                                                 45.57±80.27[d](#tfn4-ijmm-41-01-0220){ref-type="table-fn"}

P\<0.05 and

P\<0.001 vs. the control group;

P\<0.05 and

P\<0.01 vs. the SCAD group. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride; SCAD, stable coronary artery disease; ACS, acute coronary syndrome; m, male; f, female.

###### 

Primer sequences for the methylation analysis of mothers against decapentaplegic homolog 3 (Chr1:67356838-Chr1:67356942).

  Method      Primer   Sequence (5′-3′)                                              Amplicon size (bp)
  ----------- -------- ------------------------------------------------------------- --------------------
  MSP         UF       TTTAGATATTGGTTAGTTGGTTGT                                      141
              UR       ACACATTAAAAAACTCCACAACTT                                      
              MF       AGATATCGGTTAGTCGGTTGC                                         141
              MR       CATTAAAAAACTCCGCGACTT                                         
  Sequenom    F        AGGAAGAGAGGTTTTGTAATTTTTTATTTATTTGAGGG                        352
  MassARRAY   R        CAGTAATACGACTCACTATAGGGAGAAGGCTATTTTATTTCCAAAACAATAAACTCACA   

UF, unmethylated forward; UR, unmethylated reverse; MF, methylated forward; MR, methylated reverse; F, forward; R, reverse.

###### 

DM CpG sites and genes in patients with acute coronary syndrome compared with the control group.

  CpG site methylation   No. of CpG sites   No. of genes
  ---------------------- ------------------ --------------
  Loci detected          484,352            42,343
  DM                     11,342             5,073
  Hypermethylated        2,477              1,746
  Hypomethylated         8,865              5,071

CpG, 5′-C-phosphate-G-3′; DM, differentially methylated.

###### 

Frequency distribution of all significantly differentially methylated CpG sites between acute coronary syndrome and control samples by methylation status.

  ACS vs. control group methylation β score difference (%)   Hypermethylated CpG sites, n (%)   Cumulative (%)   Hypomethylated CpG sites, n (%)   Cumulative (%)
  ---------------------------------------------------------- ---------------------------------- ---------------- --------------------------------- ----------------
  ≥50                                                        24 (0.97)                          0.97             16 (0.18)                         0.18
  ≥40--\<50                                                  32 (1.29)                          2.26             22 (0.25)                         0.43
  ≥30--\<40                                                  35 (1.41)                          3.67             40 (0.45)                         0.88
  ≥20--\<30                                                  133 (5.37)                         9.04             904 (10.20)                       11.08
  ≥10--\<20                                                  2,253 (90.96)                      100              7,883 (88.92)                     100
  Total                                                      2,477                              --               8,865                             --

CpG, 5′-C-phosphate-G-3′; ACS, acute coronary syndrome.

###### 

Statistics of DM CpG sites identified by site, region and island region level.

  Test                        Region         No. of DM CpG sites   No. of genes
  --------------------------- -------------- --------------------- --------------
  CpG site-level              Whole genome   11,342                5,073
  Region-level gene based     TSS1500        861                   349
  TSS200                      421            182                   
  5′-UTR                      515            246                   
  1st Exon                    73             31                    
  Body                        2,662          1,250                 
  3′-UTR                      277            130                   
  Region-level island based   Island         1224                  462
  N-Shore                     1593           644                   
  S-Shore                     1247           513                   
  N-Shelf                     751            372                   
  S-Shelf                     685            331                   

UTR, untranslated region; CpG, 5′-C-phosphate-G-3′; DM, differentially methylated; TSS, transcription start site; N, north; S, south.

###### 

Distribution of the genomic region of significantly differentially methylated CpG sites in the acute coronary syndrome compared with the control samples.

  Genomic region of CpG sites   All CpG sites, n (%)   Hypermethylated CpG sites, n (%)   Hypomethylated CpG sites, n (%)
  ----------------------------- ---------------------- ---------------------------------- ---------------------------------
  TSS1500                       861 (17.90)            150 (15.17)                        711 (18.61)
  TSS200                        421 (8.75)             68 (6.88)                          353 (9.24)
  5′-UTR                        515 (10.71)            99 (10.01)                         416 (10.89)
  1st Exon                      73 (1.52)              17 (1.72)                          56 (1.47)
  Body                          2,662 (55.36)          597 (60.36)                        2,065 (54.06)
  3′-UTR                        277 (5.76)             58 (5.86)                          219 (5.73)
  Total                         4,809                  989                                3,820

CpG, 5′-C-phosphate-G-3′; UTR, untranslated region; TSS, transcription start site.

###### 

Distribution of island region of significantly differentially methylated GpG sites in ACS vs. control samples.

  Region level island-based GpG sites   All GpG sites   Hypermethylated CpG sites, no. (%)   Hypomethylated CpG sites, no. (%)
  ------------------------------------- --------------- ------------------------------------ -----------------------------------
  Island                                1,224 (22.25)   190 (18.50)                          1,034 (23.12)
  N-Shore                               1,593 (28.96)   304 (29.60)                          1,289 (28.82)
  S-Shore                               1,247 (22.68)   187 (18.21)                          1,060 (23.70)
  N-Shelf                               751 (13.65)     166 (16.16)                          585 (13.08)
  S-Shelf                               685 (12.46)     180 (17.53)                          505 (11.28)
  Total                                 5,500           1,027                                4,473

CpG, 5′-C-phosphate-G-3′; N, north; S, south.

###### 

KEGG pathway enrichment analysis of the hypermethylated and hypomethylated 5′-C-phosphate-G-3′ sites between the acute coronary syndrome and control samples by methylation status.

  KEGG ID no.   Pathway name                                Pathway class                         No. of genes in pathway   P-value       FDR
  ------------- ------------------------------------------- ------------------------------------- ------------------------- ------------- -------------
  hsa04640      Hematopoietic cell lineage                  Immune system                         43                        2.13×10^−7^   4.72×10^−5^
  hsa04144      Endocytosis                                 Transport and catabolism              83                        3.63×10^−7^   4.72×10^−5^
  hsa04940      Type I diabetes mellitus                    Endocrine and metabolic diseases      25                        1.55×10^−7^   1.35×10^−4^
  hsa05330      Allograft rejection                         Immune diseases                       22                        2.90×10^−6^   1.89×10^−4^
  hsa04510      Focal adhesion                              Cell communication                    80                        1.24×10^−5^   5.51×10^−4^
  hsa05320      Autoimmune thyroid disease                  Immune diseases                       24                        1.27×10^−5^   5.51×10^−4^
  hsa05145      Toxoplasmosis                               Infectious diseases: Parasitic        50                        1.51×10^−5^   5.63×10^−4^
  hsa04514      Cell adhesion molecules                     Signaling molecules and interaction   58                        2.12×10^−5^   6.90×10^−4^
  hsa04066      HIF-1 signaling pathway                     Signal transduction                   47                        2.54×10^−5^   7.17×10^−4^
  hsa04650      Natural killer cell mediated cytotoxicity   Immune system                         52                        2.76×10^−5^   7.17×10^−4^
  hsa04145      Phagosome                                   Transport and catabolism              60                        3.41×10^−5^   7.83×10^−4^
  hsa04380      Osteoclast differentiation                  Development                           54                        3.61×10^−5^   7.83×10^−4^
  hsa05332      Graft vs. host disease                      Immune diseases                       21                        4.81×10^−5^   9.63×10^−4^
  hsa04660      T cell receptor signaling pathway           Immune system                         46                        5.94×10^−5^   1.10×10^−3^
  hsa05200      Pathways in cancer                          Cancers: Overview                     113                       7.67×10^−5^   1.33×10^−3^
  hsa05146      Amoebiasis                                  Infectious diseases: Parasitic        46                        1.03×10^−4^   1.67×10^−3^
  hsa04070      Phosphatidylinositol signaling system       Signal transduction                   35                        2.66×10^−4^   4.03×10^−3^
  hsa05310      Asthma                                      Immune diseases                       16                        3.06×10^−4^   4.03×10^−3^
  hsa05416      Viral myocarditis                           Cardiovascular diseases               31                        3.10×10^−4^   4.03×10^−3^
  hsa04151      PI3K-Akt signaling pathway                  Signal transduction                   112                       3.10×10^−4^   4.03×10^−3^
  hsa05221      Acute myeloid leukemia                      Cancers: Specific types               27                        3.34×10^−4^   4.14×10^−3^
  hsa05212      Pancreatic cancer                           Cancers: Specific types               30                        4.07×10^−4^   4.82×10^−3^
  hsa04670      Leukocyte transendothelial migration        Immune system                         46                        5.73×10^−4^   6.28×10^−3^
  hsa04630      Jak-STAT signaling pathway                  Signal transduction                   53                        5.80×10^−4^   6.28×10^−3^
  hsa05166      HTLV-I infection                            Infectious diseases: Viral            89                        7.26×10^−4^   7.55×10^−3^
  hsa05032      Morphine addiction                          Substance dependence                  38                        8.19×10^−4^   8.01×10^−3^
  hsa05223      Non-small cell lung cancer                  Cancers: Specific types               25                        8.32×10^−4^   8.01×10^−3^
  hsa04062      Chemokine signaling pathway                 Immune system                         67                        9.16×10^−4^   8.32×10^−3^
  hsa04150      mTOR signaling pathway                      Signal transduction                   27                        9.29×10^−4^   8.32×10^−3^
  hsa04662      B cell receptor signaling pathway           Immune system                         32                        1.06×10^−3^   9.16×10^−3^
  hsa04915      Estrogen signaling pathway                  Endocrine system                      39                        1.30×10^−3^   1.05×10^−2^
  hsa04612      Antigen processing and presentation         Immune system                         29                        1.34×10^−3^   1.05×10^−2^
  hsa04664      Fc epsilon RI signaling pathwayc            Immune system                         30                        1.36×10^−3^   1.05×10^−2^
  hsa04060      Cytokine-cytokine receptor interaction      Signaling molecules and interaction   83                        1.37×10^−3^   1.05×10^−2^
  hsa05222      Small cell lung cancer                      Cancers: Specific types               35                        1.75×10^−3^   1.30×10^−2^
  hsa00562      Inositol phosphate metabolism               Carbohydrate metabolism               26                        2.97×10^−3^   2.15×10^−2^
  hsa05140      Leishmaniasisc                              Infectious diseases: Parasitic        28                        3.90×10^−3^   2.74×10^−2^
  hsa04666      Fcγ R-mediated phagocytosis                 Immune system                         35                        5.30×10^−3^   3.62×10^−2^
  hsa04360      Axon guidance                               Development                           47                        5.58×10^−3^   3.72×10^−2^
  hsa04725      Cholinergic synapse                         Nervous system                        41                        7.36×10^−3^   4.78×10^−2^

KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate.

###### 

List of the top 19 hypermethylated and 17 hypomethylated corresponding genes selected as possible diagnostic markers.

  A, Hypermethylated corresponding genes                                        
  ---------------------------------------- ---------- ----------- ------------- ---------
  cg03951394                               0.31859    DEAF1       4.61×10^−2^   0.43464
  cg11478607                               0.33696    GSTT1       1.43×10^−3^   0.24422
  cg01387905                               0.34720    ADAMTS2     1.35×10^−6^   0.03278
  cg13829625                               0.35709    SIN3B       1.13×10^−6^   0.03160
  cg18424635                               0.35947    HLA-DRB5    2.83×10^−2^   0.39069
  cg26951705                               0.38792    ZNF787      4.81×10^−2^   0.43861
  cg00243527                               0.39404    LIF         4.99×10^−2^   0.44222
  cg23782583                               0.40248    JAKMIP3     4.53×10^−2^   0.43270
  cg00248861                               0.40500    WHSC2       3.01×10^−2^   0.39564
  cg17005068                               0.41609    GSTT1       1.49×10^−5^   0.14324
  cg10662395                               0.46909    HCN2        3.48×10^−3^   0.24464
  cg19235645                               0.47402    FAM101A     4.16×10^−2^   0.42548
  cg21829038                               0.48534    LRRK1       3.54×10^−2^   0.41016
  cg17713488                               0.49270    COL5A3      7.66×10^−5^   0.24422
  cg14594459                               0.50806    PKHD1L1     4.34×10^−2^   0.42957
  cg18443741                               0.79680    PYROXD1     2.48×10^−5^   0.18747
  cg19577958                               0.54856    SERPINB9    4.46×10^−2^   0.43166
  cg04234412                               0.64833    LOC391322   3.49×10^−7^   0.01914
  cg16836675                               0.68159    TOM1L1      4.18×10^−3^   0.24951
                                                                                
  B, Hypomethylated corresponding genes                                         
                                                                                
  cg20592836                               −0.59591   TP53INP2    1.33×10^−2^   0.32577
  cg03549208                               −0.55680   ICA1L       3.62×10^−2^   0.41253
  cg27141807                               −0.53542   SPSB4       2.27×10^−2^   0.37233
  cg24851651                               −0.48666   CCS         1.31×10^−2^   0.32488
  cg06180910                               −0.43609   GSTT1       1.11×10^−4^   0.24422
  cg10864200                               −0.41318   PCGF3       1.12×10^−2^   0.31160
  cg24875593                               −0.40991   PDXK        5.26×10^−3^   0.26054
  cg04613734                               −0.39972   TRPS1       4.07×10^−2^   0.42315
  cg19961153                               −0.38234   ALPPL2      4.02×10^−2^   0.42219
  cg05141159                               −0.37248   DEXI        3.71×10^−2^   0.41476
  cg06049774                               −0.34306   PLAC9       9.33×10^−3^   0.29687
  cg23231631                               −0.33541   GABRB1      3.02×10^−6^   0.05052
  cg23731272                               −0.32429   SMAD3       5.37×10^−3^   0.26137
  cg08253809                               −0.32072   C14orf119   3.87×10^−2^   0.41857
  cg01655658                               −0.31142   HLA-L       4.82×10^−7^   0.02123
  cg13120108                               −0.31114   PRKCH       4.08×10^−2^   0.42353
  cg20433858                               −0.30584   OR2L13      3.36×10^−3^   0.24464

CpG, 5′-C-phosphate-G-3′; ACS, acute coronary syndrome; FDR, false discovery rate.
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